GlassScriptPhysician profile
Jeffery Moore Testani
NPI 1588729750
$545,812.39
in general payments reported to CMS, 2019-2025
21 companies · $90K in 2025
The $90K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248K · 2020: $30K · 2021: $43K · 2022: $48K · 2023: $42K · 2024: $44K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $165K · Travel and Lodging: $8,709 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,858 · Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $165,071.25 |
| Travel and Lodging | $8,708.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,858.23 |
| Food and Beverage | $484.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $184,275.13 | 2019 | |
| Eli Lilly and Company | $100,317.48 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $68,253.79 | 2019-2025 | |
| Boehringer Ingelheim International Gmbh | $46,084.52 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $40,410.00 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $24,794.29 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $23,325.60 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $22,912.50 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,937.51 | 2023 | |
| Terumo Medical Corporation | $7,875.00 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $4,680.00 | 2020-2021 | |
| Boehringer Ingelheim Canada LTD.Ltee | $3,223.71 | 2019 | |
| Edwards Lifesciences Corporation | $3,079.23 | 2021-2022 | |
| Vifor Pharma, INC. | $2,500.00 | 2020 | |
| W. L. Gore & Associates, INC. | $875.00 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $129.04 | 2019 | |
| Impulse Dynamics (USA) INC. | $79.77 | 2023 | Optimizer |
| Abiomed | $36.24 | 2023 | Impella |
| Abbott Laboratories | $23.58 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Testani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.